Cancer Registration, Molecular Marker Status, and Adherence to the WHO 2016 Classification of Pathology Reports for Glioma Diagnosed during 2017-2019 in Belgium.

IF 3.5 4区 医学 Q3 CELL BIOLOGY Pathobiology Pub Date : 2023-01-01 Epub Date: 2023-01-26 DOI:10.1159/000529320
Dimitri Vanhauwaert, Harry Pinson, Katrijn Vanschoenbeek, Franceska Dedeurwaerdere, Cindy De Gendt, Tom Boterberg, Steven De Vleeschouwer
{"title":"Cancer Registration, Molecular Marker Status, and Adherence to the WHO 2016 Classification of Pathology Reports for Glioma Diagnosed during 2017-2019 in Belgium.","authors":"Dimitri Vanhauwaert, Harry Pinson, Katrijn Vanschoenbeek, Franceska Dedeurwaerdere, Cindy De Gendt, Tom Boterberg, Steven De Vleeschouwer","doi":"10.1159/000529320","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The objective of this study was to cross-check and, if necessary, adjust registered ICD-O-3 topography and morphology codes with the findings in pathology reports available at the Belgian Cancer Registry (BCR) for glioma patients. Additionally, integration of molecular markers in the pathological diagnosis and concordance with WHO 2016 classification is investigated.</p><p><strong>Methods: </strong>Since information regarding molecular tests and corresponding conclusions are not available as structured data at population level, a manual screening of all pseudonymized pathology reports available at the BCR for registered glioma patients (2017-2019) was conducted. ICD-O-3 morphology and topography codes from the BCR database (based on information as provided by hospital oncological care programmes and pathology laboratories), were, at tumour level, cross-checked with the data from the pathology reports and, if needed, specified or corrected. Relevant molecular markers (IDH1/2, 1p19q codeletion, promoter region of the MGMT gene [MGMTp]) were manually extracted from the pathology reports.</p><p><strong>Results: </strong>In 95.3% of gliomas, the ICD-O-3 morphology code was correct. Non-specific topography codes were specified in 9.3%, while 3.3% of specific codes were corrected. The IDH status was known in 75.2% of astrocytic tumours. The rate of correct integrated diagnoses varied from 47.6% to 56.4% among different gliomas. MGMTp methylation status was available in 32.2% of glioblastomas.</p><p><strong>Conclusion: </strong>Both the integration of molecular markers in the conclusion of the pathology reports and the delivery of those reports to the BCR can be improved. The availability of distinct ICD-O-3 codes for each molecularly defined tumour entity within the WHO classification would increase the consistency of cancer registration, facilitate population level research and international benchmarking.</p>","PeriodicalId":19805,"journal":{"name":"Pathobiology","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathobiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000529320","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The objective of this study was to cross-check and, if necessary, adjust registered ICD-O-3 topography and morphology codes with the findings in pathology reports available at the Belgian Cancer Registry (BCR) for glioma patients. Additionally, integration of molecular markers in the pathological diagnosis and concordance with WHO 2016 classification is investigated.

Methods: Since information regarding molecular tests and corresponding conclusions are not available as structured data at population level, a manual screening of all pseudonymized pathology reports available at the BCR for registered glioma patients (2017-2019) was conducted. ICD-O-3 morphology and topography codes from the BCR database (based on information as provided by hospital oncological care programmes and pathology laboratories), were, at tumour level, cross-checked with the data from the pathology reports and, if needed, specified or corrected. Relevant molecular markers (IDH1/2, 1p19q codeletion, promoter region of the MGMT gene [MGMTp]) were manually extracted from the pathology reports.

Results: In 95.3% of gliomas, the ICD-O-3 morphology code was correct. Non-specific topography codes were specified in 9.3%, while 3.3% of specific codes were corrected. The IDH status was known in 75.2% of astrocytic tumours. The rate of correct integrated diagnoses varied from 47.6% to 56.4% among different gliomas. MGMTp methylation status was available in 32.2% of glioblastomas.

Conclusion: Both the integration of molecular markers in the conclusion of the pathology reports and the delivery of those reports to the BCR can be improved. The availability of distinct ICD-O-3 codes for each molecularly defined tumour entity within the WHO classification would increase the consistency of cancer registration, facilitate population level research and international benchmarking.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
比利时 2017-2019 年期间诊断的胶质瘤的癌症登记、分子标记物状态以及是否符合 2016 年世界卫生组织病理报告分类。
简介:本研究的目的是根据比利时癌症登记处(BCR)提供的胶质瘤患者病理报告结果,交叉核对并在必要时调整已注册的 ICD-O-3 拓扑学和形态学代码。此外,还研究了病理诊断中分子标记的整合以及与 2016 年世界卫生组织分类的一致性:由于有关分子检测和相应结论的信息无法以结构化数据的形式在人群水平上获得,因此对 BCR 登记的胶质瘤患者(2017-2019 年)的所有化名病理报告进行了人工筛选。在肿瘤层面,将 BCR 数据库中的 ICD-O-3 形态学和地形学代码(基于医院肿瘤护理计划和病理实验室提供的信息)与病理报告中的数据进行交叉核对,并在必要时进行指定或更正。相关分子标记物(IDH1/2、1p19q缺失、MGMT基因启动子区域[MGMTp])由人工从病理报告中提取:在 95.3% 的胶质瘤中,ICD-O-3 形态学代码是正确的。9.3%的脑胶质瘤指定了非特异性地形编码,3.3%的特异性编码得到了更正。75.2%的星形细胞瘤的 IDH 状态是已知的。不同胶质瘤的综合诊断正确率从 47.6% 到 56.4% 不等。32.2%的胶质母细胞瘤可获得MGMTp甲基化状态:结论:在病理报告结论中整合分子标记物以及向 BCR 提供这些报告的工作都有待改进。为世卫组织分类中每个分子定义的肿瘤实体提供不同的 ICD-O-3 编码将提高癌症登记的一致性,促进人群研究和国际基准的制定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pathobiology
Pathobiology 医学-病理学
CiteScore
8.50
自引率
0.00%
发文量
47
审稿时长
>12 weeks
期刊介绍: ''Pathobiology'' offers a valuable platform for the publication of high-quality original research into the mechanisms underlying human disease. Aiming to serve as a bridge between basic biomedical research and clinical medicine, the journal welcomes articles from scientific areas such as pathology, oncology, anatomy, virology, internal medicine, surgery, cell and molecular biology, and immunology. Published bimonthly, ''Pathobiology'' features original research papers and reviews on translational research. The journal offers the possibility to publish proceedings of meetings dedicated to one particular topic.
期刊最新文献
Nodal T-cell lymphoma transdifferentiated from mantle cell lymphoma with Epstein-Barr virus infection. Human Papilloma Virus-Related Oral Mucosal Lesions in Turkey: A Retrospective Cohort Study. Next-Generation Integrated Sequencing Identifies Poor Prognostic Factors in Patients with MYD88-Mutated Chronic Lymphocytic Leukemia in Taiwan. p16 Immunohistochemical Patterns in Triple-Negative Breast Cancer: Clinical and Genomic Similarities of the p16 Diffuse Pattern to pRB Deficiency. Artificial Intelligence Recognition Model Using Liquid-Based Cytology Images to Discriminate Malignancy and Histological Types of Non-Small-Cell Lung Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1